Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Mar 31, 2017
Filed with the SEC on Apr 28, 2017 and accepted by EDGAR at Apr 28, 2017, 20:22 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2017-01-01 to 2017-03-31 | $273.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-01-01 to 2017-03-31 | $113.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-01-01 to 2017-03-31 | $270.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-01-01 to 2017-03-31 | $4.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-01-01 to 2017-03-31 | $247.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-01-01 to 2017-03-31 | $0.99 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-01-01 to 2017-03-31 | $1.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-01-01 to 2017-03-31 | 248,700,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2017-01-01 to 2017-03-31 | $265.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2017-01-01 to 2017-03-31 | $11.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-03-31 | $1.00bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-03-31 | $1.87bn | us-gaap:AssetsCurrent |
| Total assets | At period end2017-03-31 | $2.95bn | us-gaap:Assets |
| Current liabilities | At period end2017-03-31 | $489.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-03-31 | $1.26bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-03-31 | $1.50bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-17-000030. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.